What is the clinical evidence from this study?

Study design: Review. Population: Hypertension and cardiovascular disease. Intervention: Candesartan cilexetil vs. Placebo or other active treatments.

What question did this study set out to answer?

To review the pharmacological properties, comparative antihypertensive efficacy, and cardiovascular outcome data for candesartan cilexetil across diverse patient populations.

December 1, 2011Vascular Health and Risk ManagementOpen Access

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Q: What are the key findings of this study?

Candesartan cilexetil is an effective antihypertensive agent that provides cardiovascular and renal protection with a tolerability profile similar to placebo.

Q: What does this research mean for the field?

Candesartan cilexetil is an effective antihypertensive agent that provides cardiovascular and renal protection with a tolerability profile similar to placebo. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Candesartan lowers blood pressure with cardioprotective and renal benefits and placebo-like tolerability.

Why the study?

Does candesartan provide better antihypertensive efficacy and clinical outcomes compared to other ARBs in adult patients with hypertension?

Key Points

To review the pharmacological properties, comparative antihypertensive efficacy, and cardiovascular outcome data for candesartan cilexetil across diverse patient populations.
Synthesized data from multiple randomized clinical trials evaluating oral candesartan cilexetil (8–32 mg once daily) in diverse adult patient cohorts.
Assessed clinical outcomes across populations with prehypertension, hypertension, chronic heart failure with reduced or preserved ejection fraction, type 2 diabetes, and renal disease.
In patients with heart failure and left ventricular systolic dysfunction intolerant to ACE inhibitors, 32 mg candesartan cilexetil reduced cardiovascular mortality or heart failure hospitalization by 23% compared with placebo (HR: 0.77, 95% CI: 0.67–0.89, P = 0.0004).
In the CHARM-Added trial, adding 32 mg candesartan cilexetil to ACE inhibitor therapy significantly reduced cardiovascular death or heart failure hospitalization compared with placebo (38% vs 42%, HR: 0.85, P = 0.011).
In the TROPHY trial (N=772), candesartan cilexetil significantly lowered the development of hypertension versus placebo at 2 years (53 vs 154 participants, relative risk reduction 66.3%, P < 0.001) and at 4 years (208 vs 240, relative risk reduction 15.6%, P < 0.007).

Structured PICO

Does candesartan provide better antihypertensive efficacy and clinical outcomes compared to other ARBs in adult patients with hypertension?

Population

A narrative review of clinical trials evaluating candesartan cilexetil in adult patients with hypertension, heart failure, and related cardiovascular or renal conditions.

Intervention

Candesartan cilexetil (oral 8-32 mg once daily)

Comparator

Other ARBs (losartan, telmisartan, valsartan) or placebo

This review highlights that candesartan is highly effective for blood pressure control and cardiovascular risk reduction, with efficacy superior to losartan and comparable to telmisartan and valsartan.

Implication

May inform ARB choice in hypertension; leaves open need for dedicated outcome trials versus other agents.

Abstract

The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8-32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Reuven Zimlichman (2011) conducted a review in Hypertension and cardiovascular disease. Candesartan cilexetil vs. Placebo or other active treatments was evaluated. Candesartan cilexetil is an effective antihypertensive agent that provides cardiovascular and renal protection with a tolerability profile similar to placebo.

synapsesocial.com/papers/6a1fdb629d62e9997c04939d https://doi.org/10.2147/vhrm.s22591

View Full Paper

Ask AI

Bookmark

Implication

May inform ARB choice in hypertension; leaves open need for dedicated outcome trials versus other agents.

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading